ROVI.MC RO

ROVI.MC LABORATORIOS FARMACEUTICOS ROVI

Healthcare · Drug Manufacturers - Specialty & Generic

7 · Fair Safe

58.70

+0.17%

About the company

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.

1.64% 37.21% 0.96 3.0B 22.75 2.58 67.48
52w 51.65 86.70
Yield Growth Safety Value Health

Dividend profile

Frequency Annual Growth (TTM) -15.3% CAGR 3y -0.7% +39.8% 0 years

Payment calendar

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

Valuation & strategy

41.40
Passes the threshold
Fairly valued
Yield 1.64% vs 5-yr 0.66%–2.67%
Implied fair price
58.54 EUR

Read-only estimates from public data — not advice.

Dividend history

14 15 16 17 18 19 20 21 22 23 24 25

Per-share dividend by year

Debt & leverage

16.66%
3.65
1.77
Total debt
114.4M EUR
Total cash
97.4M EUR
183.4M EUR

Latest reported balance-sheet figures.

Sign up for an AI summary of this stock's dividend — and to track it in your portfolio.

Information, not financial advice.

The information on Quantic is provided for informational and educational purposes only. It is general in nature, does not take into account your personal financial situation, and does not constitute investment, financial, tax, or legal advice — nor a recommendation to buy or sell any security. Investing involves risk, including possible loss of principal; past performance is not a reliable indicator of future results. Market data comes from third-party providers and may be delayed or inaccurate. Before making any investment decision, consider your objectives, time horizon, risk tolerance, and diversification, and consult a qualified financial professional. Quantic is not a registered investment adviser or broker-dealer.

Quantic finance

Built with Elixir, Phoenix LiveView, and Tailwind CSS

© 2026 Francesc Leveque · Learn · Frequently Asked Questions